Commentary: U.S. government in next two years critical to biotech gains

04/27/2007 | Wall Street Journal, The

In just 30 years, the biotechnology industry in the U.S. has "helped transform science into real cures" for some diseases. The next 30 years of the industry could lead to other unmet needs in medicine, but the way Congress handles industry issues related to pricing, safety and generics over the next two years will be critical, writes Biogen Idec CEO and BIO chairman James Mullen in a commentary.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care